Academic Journal
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial.
| Τίτλος: | Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial. |
|---|---|
| Συγγραφείς: | Hörner M; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Schäffler H; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany., Häberle L; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.; Biostatistics Unit, Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Erlangen, Germany., Goossens C; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Pfister K; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany., Leinert E; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany., Veselinovic K; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany., Brucker SY; Department of Women's Health, Tuebingen University, Tuebingen, Germany., Köhler U; Department of Gynecology and Obstetrics, Klinikum St. Georg, Leipzig, Germany., Heinrich G; Schwerpunktpraxis der Gynäkologie und Onkologie Fürstenwalde, Klinikum Offenbach, Fürstenwalde, Germany., Schneeweiss A; National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Beckmann MW; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Fasching PA; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany., Janni W; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany., Rack B; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany., Heublein S; Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany., Ziegler P; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. |
| Πηγή: | International journal of cancer [Int J Cancer] 2026 Oct 15; Vol. 159 (8), pp. 1990-2003. Date of Electronic Publication: 2026 Apr 29. |
| Τύπος έκδοσης: | Comparative Study; Journal Article; Randomized Controlled Trial |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE |
| Imprint Name(s): | Publication: 1995- : New York, NY : Wiley-Liss Original Publication: 1966-1984 : Genève : International Union Against Cancer |
| Ιατρικοί όροι (MeSH): | Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Nausea*/chemically induced , Nausea*/epidemiology , Vomiting*/chemically induced , Vomiting*/epidemiology, Chemotherapy, Adjuvant/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Epirubicin/administration & dosage ; Epirubicin/adverse effects ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Taxoids/administration & dosage ; Taxoids/adverse effects ; Adult ; Aged ; Female ; Humans ; Middle Aged ; Docetaxel |
| Περίληψη: | Chemotherapy-induced nausea and vomiting (CINV) remains an important side effect despite new antiemetic drugs. This study tried to understand the occurrence of CINV in patients receiving two different chemotherapy regimens. As part of the randomized controlled clinical trial SUCCESS C (NCT00847444), 1582 of the 3463 patients completed CINV diaries. Patients were randomized to receive either chemotherapy with FEC (5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel) or TC (docetaxel, cyclophosphamide). CINV was evaluated hourly using a specially designed questionnaire. Endpoints of the study were complete response (no emesis) and total control (no nausea and no emesis) and were assessed with Kaplan-Meier curves and Cox regression analyses over three chemotherapy cycles. Eight hundred fourteen patients received FEC and 768 received TC; patients and tumor characteristics were similar in both groups. Patients receiving FEC had significantly more nausea and vomiting, with the main difference in the first 12 h. In the first cycle, the 0-12-h nausea/emesis-free rates were 70%/41% for FEC and 91/76% for TC. By 24 h after chemotherapy, the rates were 65%/33% (FEC) and 85%/60% (TC). The differences were similar in cycles 2 and 3. The detailed analysis of CINV in the study is unique and paves the way for modern CINV analysis of new therapeutics such as antibody-drug conjugates. (© 2026 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.) |
| References: | Support Care Cancer. 2010 Jul;18(7):869-76. (PMID: 19701781) Front Pharmacol. 2020 Apr 01;11:329. (PMID: 32296333) Support Care Cancer. 2013 Feb;21(2):565-73. (PMID: 22869054) J Clin Oncol. 2022 Jan 10;40(2):180-188. (PMID: 34793245) J Clin Oncol. 1990 Jun;8(6):1063-9. (PMID: 2140854) Eur J Cancer. 2016 May;58:122-9. (PMID: 26994459) Circulation. 2010 Apr 6;121(13):1518-22. (PMID: 20368531) Psychosom Med. 2016 Oct;78(8):959-965. (PMID: 27428859) J Clin Oncol. 2020 Aug 20;38(24):2782-2797. (PMID: 32658626) Br J Cancer. 2022 Jun;126(12):1715-1724. (PMID: 35194193) Rev Saude Publica. 2020 Nov 09;54:106. (PMID: 33175025) Clin Pharmacokinet. 1999 Feb;36(2):99-114. (PMID: 10092957) Br J Clin Pharmacol. 1979 Sep;8(3):209-17. (PMID: 497087) Eur J Cancer Clin Oncol. 1985 Nov;21(11):1307-13. (PMID: 3865777) J Clin Oncol. 1997 Jan;15(1):103-9. (PMID: 8996130) Eur J Cancer. 1999 Feb;35(2):296-301. (PMID: 10448274) N Engl J Med. 2008 Jun 5;358(23):2482-94. (PMID: 18525044) ESMO Open. 2022 Aug;7(4):100553. (PMID: 35964548) BMC Pregnancy Childbirth. 2021 Feb 19;21(1):152. (PMID: 33607953) Chronobiol Int. 2017;34(4):480-491. (PMID: 28362229) Clin Transl Radiat Oncol. 2016 Dec 27;2:1-6. (PMID: 29657992) Int J Clin Oncol. 2015 Oct;20(5):855-65. (PMID: 25681876) Ann Oncol. 2017 Jun 01;28(6):1260-1267. (PMID: 28398530) J Cancer. 2023 Aug 28;14(14):2644-2654. (PMID: 37779870) |
| Grant Information: | Sanofi-Aventis Deutschland; Chugai Pharmaceutical; Pfizer; GlaxoSmithKline |
| Contributed Indexing: | Keywords: chemotherapy; chemotherapy‐induced nausea and vomiting (CINV); early breast cancer; randomized clinical trial |
| Substance Nomenclature: | 8N3DW7272P (Cyclophosphamide) 15H5577CQD (Docetaxel) 3Z8479ZZ5X (Epirubicin) U3P01618RT (Fluorouracil) 0 (Taxoids) |
| Entry Date(s): | Date Created: 20260429 Date Completed: 20260821 Latest Revision: 20260903 |
| Update Code: | 20260903 |
| PubMed Central ID: | PMC13495824 |
| DOI: | 10.1002/ijc.70528 |
| PMID: | 42056728 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!